Related Experiment Video
Updated: Jun 20, 2026
10:32
Development of a Virtual Reality Assessment of Everyday Living Skills
Published on: April 23, 2014
Lurasidone: a new drug in development for schizophrenia
Jonathan M Meyer1, Antony D Loebel, Edward Schweizer
1Department of Psychiatry, University of California, San Diego, CA 92161, USA. jmmeyer@ucsd.edu
Expert Opinion on Investigational Drugs
|September 29, 2009
Summary
Lurasidone, a novel antipsychotic, shows efficacy in schizophrenia treatment by targeting dopamine D2 and serotonin 5-HT2A receptors. Early studies indicate potential cognitive benefits and a favorable safety profile regarding QTc prolongation and metabolic effects.
Area of Science:
- Psychopharmacology
- Neuroscience
- Clinical Pharmacology
Background:
- Lurasidone is an investigational psychotropic medication.
- It is being developed for schizophrenia and bipolar disorder treatment.
Purpose of the Study:
- To detail the development of lurasidone.
- To review its receptor binding, pharmacokinetics, and CNS activity.
- To present early human clinical efficacy and safety data.
Main Methods:
- Literature review of published data and sponsor-held information.
- Analysis of receptor binding affinities.
- Evaluation of preclinical CNS activity in rodent models.
- Review of early-phase clinical trial results.
Main Results:
- Lurasidone exhibits high affinity for dopamine D2 and serotonin 5-HT2A receptors.
- It also binds to receptors associated with cognitive function enhancement (e.g., 5-HT7, 5-HT1A).
- Lurasidone demonstrates a favorable receptor binding profile with low affinity for certain off-target receptors (e.g., M1, H1).
- Phase II studies show efficacy in schizophrenia treatment (40-120 mg/day), particularly for positive symptoms.
- Preclinical data suggest reversal of cognitive impairment in rodents.
- Early clinical data indicate potential cognitive effects and no significant QTc prolongation or adverse metabolic changes.
Conclusions:
- Lurasidone possesses a unique receptor binding profile.
- It demonstrates efficacy and a promising safety profile in early clinical development for schizophrenia.
- Further research is warranted to fully elucidate its therapeutic potential, especially regarding cognitive function.
Related Concept Videos
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:21Antipsychotic Drugs: Typical and Atypical Agents
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
01:21Antipsychotic Drugs: Therapeutic Uses and Side Effects
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...